摘要
鲁拉西酮是一种新型抗精神障碍药(第二代抗精神病药SGA),是多巴胺2型D2和血清素5-HT2A和5-HT7受体完全拮抗剂和部分5-HT1A受体激动剂。鲁拉西酮对精神分裂症患者的精神病症状、感情症状、认知症状的治疗效果明显,同时对患者体重、代谢影响水平较小,具有良好的安全性及耐受性,广泛应用于临床治疗。本文综述了鲁拉西酮的作用机制和药动学、群体药动学、安全性、有效性及耐受性、治疗药物检测、基因多态性、药物相互作用研究现状,以期为后续研究及临床个体化用药提供参考。
Lurasidone is a novel antipsychotic(second-generation antipsychotic SGA),which is a complete antagonist of dopamine type 2(D2)and serotonin 5-HT2A and 5-HT7 receptors and a partial 5-HT1A receptor agonist.It is widely used in the clinical treatment of patients with schizophrenia because of its significant efficacy in psychotic,affective,and cognitive symptoms,and its low effect on body mass and metabolism,as well as its good safety and tolerability.Based on this,the review focuses on the mechanism of action and pharmacokinetic studies,population pharmacokinetics,safety,efficacy and tolerability,therapeutic drug testing,gene polymorphism,and drug interaction studies of lurasidone,with the aim of providing reference for follow-up studies and individualized clinical treatment.
作者
陈玉清
杨烨
戴丽静
温预关
CHEN Yuqing;YANG Ye;DAI Lijing;WEN Yuguan(Phase I Clinical Laboratory of Brain Hospital Affiliated to Guangzhou Medical University,Guangzhou 510370,China)
出处
《广东药科大学学报》
CAS
2023年第5期126-134,共9页
Journal of Guangdong Pharmaceutical University
基金
广东省医院药学研究基金资助项目(澳美基金,2022A22)
广东省药学会临床治疗精准用药专项基金(2023JZ14)
广东省卫生计生适宜推广基金资助项目(粤卫办函[2018]326号)。
关键词
鲁拉西酮
药代动力学
治疗药物检测
群体药代动力学
基因多态性
个体化用药
lurasidone
pharmacokinetics
therapeutic drug monitoring
population pharmacokinetics
genetic polymorphisms
individual medication
